ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Calliditas Therapeutics Ab

Calliditas Therapeutics Ab (0A5R)

0.00
0.00
(0.00%)
Cerrado 24 Noviembre 10:30AM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
-
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
-
Precio de Apertura
-
Hora
Última hora de negociación
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

0A5R Últimas noticias

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...

Interim Report Q2, 2023: Calliditas Therapeutics

Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire STOCKHOLM, Aug. 17, 2023 Filing for full approval of TARPEYO STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM, May 30, 2023 /PRNewswire/ -- The following resolutions were passed at...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SCGLSealand Capital Galaxy Limited
0.21p
(50.00%)
219.35M
PPSProton Motor Power Systems Plc
0.175p
(40.00%)
3.79M
PXCPhoenix Copper Limited
7.00p
(37.25%)
5.13M
SLFRSlf Realisation Fund Limited
1.49p
(29.57%)
827.89k
NWORNational World Plc
19.00p
(26.67%)
2.74M
WEBWebis Holdings Plc
0.125p
(-68.75%)
28.06M
HEMOHemogenyx Pharmaceuticals Plc
1.15p
(-24.59%)
102.87M
AMGOAmigo Holdings Plc
0.525p
(-16.67%)
15.73M
PLAZPlaza Centers N.v.
25.00p
(-16.67%)
2k
AURRAurrigo International Plc
52.50p
(-15.32%)
66.25k
NTVONativo Resources Plc
0.0026p
(13.04%)
4.92B
CPXCap-xx Limited
0.14p
(9.80%)
395.59M
NTOGNostra Terra Oil And Gas Company Plc
0.02275p
(-4.21%)
394.31M
VELAVela Technologies Plc
0.007p
(-6.67%)
336.14M
MSMNMosman Oil And Gas Limited
0.0395p
(-3.66%)
314.18M
Jim Beem Jim Beem 5 minutos hace
SEC DELINQUENT NOTICE ON ASII
ASII
BDEZ BDEZ 7 minutos hace
For sure!
georgejjl georgejjl 8 minutos hace
News that is IMMINENT

A lot of news to be expected prior to the end of the year 2024

Alzheimer’s disease: Data from the blarcamesine Phase 2b/3 ANAVEX®2-73-AD-004 trial to be published in an upcoming peer-reviewed journal

Alzheimer’s disease: Full reg
AVXL
stockhero stockhero 12 minutos hace
I've been trying to buy pizza and subs for the past 10 years.
GMPR
tredenwater2 tredenwater2 12 minutos hace
“ I agree, crescent, that the announcement this evening is quite unusual.”

Its quite a bit different than last time they released data by releasing their past trial data twice, one week apart. The first time the stock wd t absolutely nowhere. The second time they released it the stock
AVXL
north40000 north40000 12 minutos hace
Paid full price for Brand Vascepa last time(after 7/01/2024). 

Typo: There is a patent infringement suit in Delaware, not yet an antitrust suit there.
AMRN
3331 3331 14 minutos hace
BIEL (Bioelectronics): #5 BREAKOUT BOARD + #5 MOST READ (last hour)!
blackhawks blackhawks 15 minutos hace
Hey Trump Voters .........

https://i.postimg.cc/sxY6Q0K0/IMG-4787.jpg
blackhawks blackhawks 16 minutos hace
Hey Trump Voters .........

https://i.postimg.cc/sxY6Q0K0/IMG-4787.jpg
MysticCentaur11 MysticCentaur11 17 minutos hace
https://yougotsmarter.com/best-fishing-partner-gifts/ Bump.
pos_stock_hoarder pos_stock_hoarder 17 minutos hace
A great idea! The BEE stings again.
dinogreeves dinogreeves 19 minutos hace
Schwab just halted borrows on SMCI. Lets see in the morning if this has any merits.
SMCI
leverage102 leverage102 20 minutos hace
I may jump in tomorrow.

Thanks
SFIO
Turbomunkey Turbomunkey 21 minutos hace
3 more weeks of this and youre going to see me on the evening news.
NXPL
dinogreeves dinogreeves 23 minutos hace
VCNX is getting marinated and prepped for a major run. How fast and far up, all depends on what the insiders motives are. The science is one of the best breeds out there. This could fly to 20 dollars and still be cheap. Hands down the next DRU*G in the making and even higher in the triple dollar
VCNX
mrfence mrfence 24 minutos hace
$FMCC~ $FNMA~
[yt]ojULkWEUsPs?si=8v4gJoCdDPdl5068[/yt]
FMCC FNMA
TucsonPhil TucsonPhil 24 minutos hace
Halted after 4pm on Friday, before FDA approval news.

Should spike on Monday!
BBIO
umtiti umtiti 25 minutos hace
https://forums.garmin.com/developer/connect-iq/f/showcase/393304/new-updated-how-to-get-free-dice-on-monopoly-go-ultimate-guide-to-monopoly-go-free-dice-november-2024
https://forums.garmin.com/developer/connect-iq/f/showcase/393316/updated-new-750-free-shein-gift-cards---how-to-get-free-shein
aheadofthecurve aheadofthecurve 25 minutos hace
I'm clueless buddy. I don't get it.
I tell ya though I've seen a lot of articles or publishing etc since they've gone EM
RSPI
arizona1 arizona1 25 minutos hace
So many police and military. Everywhere.

I think we're about to relive it. This is what white MAGA wants.
gp22 gp22 26 minutos hace
$VVOS @ $3.13: Microfloat. Cash rich. Recent FDA Approval of only device for Sleep Apnea. Upgraded last week to $6.00 Valuation.
Coming off lows on elevated volume last week. Likely moves very nicely in coming sessions
VVOS
gdl gdl 26 minutos hace
investing.com-- U.S. stock index futures rose in evening deals on Sunday as Wall Street appeared to be relieved by President-elect Donald Trump nominating prominent investor Scott Bessent as Treasury Secretary.

Futures were buoyed by a persistent rotation into cyclical and economical
LLY
aheadofthecurve aheadofthecurve 27 minutos hace
I agree. 
RSPI

Su Consulta Reciente

Delayed Upgrade Clock